Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency

Glioblastoma remains the most common, malignant primary cancer of the central nervous system with a low life expectancy and an overall survival of less than 1.5 years. The treatment options are limited and there is no cure. Moreover, almost all patients develop recurrent tumors, which typically are...

Descripción completa

Detalles Bibliográficos
Autores principales: Doan, Ninh B., Alhajala, Hisham, Al-Gizawiy, Mona M., Mueller, Wade M., Rand, Scott D., Connelly, Jennifer M., Cochran, Elizabeth J., Chitambar, Christopher R., Clark, Paul, Kuo, John, Schmainda, Kathleen M., Mirza, Shama P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762539/
https://www.ncbi.nlm.nih.gov/pubmed/29348854
http://dx.doi.org/10.18632/oncotarget.22637

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5762539/
https://www.ncbi.nlm.nih.gov/pubmed/29348854
http://dx.doi.org/10.18632/oncotarget.22637

Ejemplares similares